SEMA3F and ductal breast carcinoma in situ: Finally, to determine the clinical relevance of SEMA3F in DCIS transition to IDC, DCIS tumors and DCIS + IDC tumors from BC patients were also stained for SEMA3F, which was greater in invasive patients than in DCIS patients (Fig. 1g); these findings indicate that SEMA3F could be a poor prognostic marker in DCIS patients.